Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Controlled release cgrp delivery composition for cardiovascular and renal indications

a technology of cgrp and delivery composition, which is applied in the direction of drug compositions, antinoxious agents, peptide/protein ingredients, etc., can solve the problems of iv administration and dosages that could only be administered intravenously, and achieve the effects of reducing or attenuating deleterious effects, reducing doses, and prolonging administration tim

Inactive Publication Date: 2011-10-06
VASOGENIX PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The controlled release of CGRP effectively treats heart failure by maintaining hemodynamic stability, reducing the progression of heart failure symptoms, and improving renal function, offering a safer and more effective treatment compared to current therapies, potentially reducing hospitalizations and healthcare costs.

Problems solved by technology

However, these doses could only be administered intravenously for about 12-24 hours before unwanted side effects set in and the IV administration had to be discontinued.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026]One aspect of this invention provides improved methods for administering CGRP to a patient having HF in a manner effective to treat or prevent HF. The “patient” can be any living organism, including a warm-blooded mammal such as a human. The treatment according to any of the methods of this invention can be administered on an inpatient such as a hospital or emergency room, or in an outpatient setting such as a hospice or home health care setting or administration by emergency care personnel to a patient having a myocardial infarction. This invention further provides methods of improving hemodynamic functions in a patient with HF by providing improved methods of administering CGRP to the patient in either an inpatient or outpatient setting.

[0027]“Treating HF” as used herein refers to treating any one or more of the conditions underlying HF, including, without limitation, decreased cardiac contractility, abnormal diastolic compliance, reduced stroke volume, pulmonary congestion,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods of treating heart failure and improving renal function, and / or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies.

Description

BACKGROUND OF TILE INVENTION[0001]1. Field of the Invention[0002]The present invention provides methods for treating heart failure improving renal function, preventing or delaying the advancement of heart failure into advanced stages, and counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation.[0003]2. Description of the Prior Art[0004]Heart failure is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood, and the heart works less efficiently than it should. Heart failure is characterized by specific symptoms (e.g., dyspnea and fatigue) which may limit exercise tolerance and signs (e.g., fluid retention) which may lead to pulmonary congestion and peripheral edema. Both abnormalities can impair the functional capacity and quality of life of affected indivi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/14A61K38/02A61P9/10A61K9/00A61K9/16A61K9/70A61K38/22A61K47/48
CPCA61K9/0024A61K9/1647A61K47/4823A61K38/225A61K47/48215A61K9/7007A61K47/60A61K47/61A61P13/12A61P9/04A61P9/10
Inventor SOUTHARD, JEFFREY L.SOUTHARD, GEORGE L.
Owner VASOGENIX PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com